Mirati’s KRAS-blocking Lung Cancer Drug Clears Safety Hurdle in Combination Study

Mirati Therapeutics said this week that its KRAS-targeting cancer drug adagrasib combined with another immunotherapy was well-tolerated by lung cancer patients.